Edgewise Therapeutics
Marcus Henze currently serves as Associate Director of Pharmacology at Edgewise Therapeutics since October 2022. Prior experience includes roles as Scientific Associate Director and Senior Scientist in Pharmacology at Bristol Myers Squibb from November 2020 to April 2022, and Senior Scientist in Pharmacology at MyoKardia from October 2014 to November 2020. Earlier, Marcus was a Postdoctoral Research Associate at the University of Illinois at Chicago from August 2009 to August 2014 under John R. Solaro. Marcus began the career in cytogenetics, working as a Cytogenetic Technologist at both Rush University Medical Center and Detroit Medical Center from 1995 to 2002, focusing on chromosomal analysis. Educational qualifications include a Ph.D. in Pharmacology from Loyola University Chicago Stritch School of Medicine and a B.S. in Microbiology from Michigan State University.
This person is not in any teams
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.